Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(3.96)
# 593
Out of 4,970 analysts
12
Total ratings
68.75%
Success rate
9.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XNCR Xencor | Maintains: Overweight | $33 → $27 | $8.37 | +222.58% | 3 | Aug 7, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $26 → $25 | $11.56 | +116.26% | 3 | Aug 7, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $30 → $42 | $35.51 | +18.28% | 2 | Jul 9, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $44 | $25.83 | +70.34% | 1 | Jun 26, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $12.07 | -33.72% | 2 | May 23, 2025 | |
| MRUS Merus | Maintains: Overweight | $91 → $89 | $66.22 | +34.40% | 1 | May 8, 2025 |
Xencor
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $8.37
Upside: +222.58%
Arcus Biosciences
Aug 7, 2025
Maintains: Overweight
Price Target: $26 → $25
Current: $11.56
Upside: +116.26%
Kiniksa Pharmaceuticals International,
Jul 9, 2025
Maintains: Overweight
Price Target: $30 → $42
Current: $35.51
Upside: +18.28%
IDEAYA Biosciences
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $25.83
Upside: +70.34%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $12.07
Upside: -33.72%
Merus
May 8, 2025
Maintains: Overweight
Price Target: $91 → $89
Current: $66.22
Upside: +34.40%